Aptorum Group (APM) Competitors $0.86 0.00 (-0.11%) As of 12:40 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock APM vs. ANEB, XCUR, QNCX, QNTM, and LPCNShould you buy Aptorum Group stock or one of its competitors? MarketBeat compares Aptorum Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aptorum Group include Anebulo Pharmaceuticals (ANEB), Exicure (XCUR), Quince Therapeutics (QNCX), Quantum Biopharma (QNTM), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. APM vs. ANEBAPM vs. XCURAPM vs. QNCXAPM vs. QNTMAPM vs. LPCNHow does Aptorum Group compare to Anebulo Pharmaceuticals?Anebulo Pharmaceuticals (NASDAQ:ANEB) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations. Which has more risk & volatility, ANEB or APM? Anebulo Pharmaceuticals has a beta of -1.93, meaning that its stock price is 293% less volatile than the broader market. Comparatively, Aptorum Group has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Is ANEB or APM more profitable? Aptorum Group's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Anebulo PharmaceuticalsN/A -74.57% -68.96% Aptorum Group N/A N/A N/A Which has higher valuation and earnings, ANEB or APM? Aptorum Group has higher revenue and earnings than Anebulo Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnebulo PharmaceuticalsN/AN/A-$8.48M-$0.19N/AAptorum Group$430K12.64-$1.36MN/AN/A Do analysts recommend ANEB or APM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do institutionals & insiders hold more shares of ANEB or APM? 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Comparatively, 64.0% of Aptorum Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor ANEB or APM? In the previous week, Anebulo Pharmaceuticals' average media sentiment score of 0.00 equaled Aptorum Group'saverage media sentiment score. Company Overall Sentiment Anebulo Pharmaceuticals Neutral Aptorum Group Neutral SummaryAptorum Group beats Anebulo Pharmaceuticals on 5 of the 8 factors compared between the two stocks.How does Aptorum Group compare to Exicure?Exicure (NASDAQ:XCUR) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation. Which has better valuation & earnings, XCUR or APM? Aptorum Group has lower revenue, but higher earnings than Exicure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$500K35.23-$4.95M-$0.77N/AAptorum Group$430K12.64-$1.36MN/AN/A Does the media refer more to XCUR or APM? In the previous week, Exicure had 1 more articles in the media than Aptorum Group. MarketBeat recorded 1 mentions for Exicure and 0 mentions for Aptorum Group. Aptorum Group's average media sentiment score of 0.00 beat Exicure's score of -0.71 indicating that Aptorum Group is being referred to more favorably in the news media. Company Overall Sentiment Exicure Negative Aptorum Group Neutral Do analysts rate XCUR or APM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more risk & volatility, XCUR or APM? Exicure has a beta of 3.62, meaning that its stock price is 262% more volatile than the broader market. Comparatively, Aptorum Group has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Is XCUR or APM more profitable? Aptorum Group's return on equity of 0.00% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -138.71% -62.76% Aptorum Group N/A N/A N/A Do institutionals and insiders have more ownership in XCUR or APM? 42.8% of Exicure shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 52.8% of Exicure shares are owned by insiders. Comparatively, 64.0% of Aptorum Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryExicure and Aptorum Group tied by winning 5 of the 10 factors compared between the two stocks.How does Aptorum Group compare to Quince Therapeutics?Quince Therapeutics (NASDAQ:QNCX) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership. Do institutionals and insiders have more ownership in QNCX or APM? 30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Aptorum Group shares are held by institutional investors. 20.3% of Quince Therapeutics shares are held by insiders. Comparatively, 64.0% of Aptorum Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger earnings and valuation, QNCX or APM? Aptorum Group has higher revenue and earnings than Quince Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$83.98M-$10.62N/AAptorum Group$430K12.64-$1.36MN/AN/A Is QNCX or APM more profitable? Aptorum Group's return on equity of 0.00% beat Quince Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -372.88% -67.99% Aptorum Group N/A N/A N/A Do analysts recommend QNCX or APM? Quince Therapeutics presently has a consensus target price of $65.00, indicating a potential upside of 5,890.78%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Quince Therapeutics is more favorable than Aptorum Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more risk and volatility, QNCX or APM? Quince Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Aptorum Group has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Does the media favor QNCX or APM? In the previous week, Quince Therapeutics had 8 more articles in the media than Aptorum Group. MarketBeat recorded 8 mentions for Quince Therapeutics and 0 mentions for Aptorum Group. Quince Therapeutics' average media sentiment score of 0.17 beat Aptorum Group's score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Quince Therapeutics Neutral Aptorum Group Neutral SummaryQuince Therapeutics beats Aptorum Group on 6 of the 11 factors compared between the two stocks.How does Aptorum Group compare to Quantum Biopharma?Quantum Biopharma (NASDAQ:QNTM) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends. Which has more risk and volatility, QNTM or APM? Quantum Biopharma has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, Aptorum Group has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Do analysts rate QNTM or APM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is QNTM or APM more profitable? Aptorum Group's return on equity of 0.00% beat Quantum Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Quantum BiopharmaN/A -941.54% -224.41% Aptorum Group N/A N/A N/A Which has stronger earnings & valuation, QNTM or APM? Aptorum Group has higher revenue and earnings than Quantum Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuantum BiopharmaN/AN/A-$26.17M-$8.25N/AAptorum Group$430K12.64-$1.36MN/AN/A Does the media favor QNTM or APM? In the previous week, Quantum Biopharma had 3 more articles in the media than Aptorum Group. MarketBeat recorded 3 mentions for Quantum Biopharma and 0 mentions for Aptorum Group. Quantum Biopharma's average media sentiment score of 0.20 beat Aptorum Group's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the media. Company Overall Sentiment Quantum Biopharma Neutral Aptorum Group Neutral Do insiders & institutionals hold more shares of QNTM or APM? 1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 3.8% of Aptorum Group shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by company insiders. Comparatively, 64.0% of Aptorum Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryAptorum Group beats Quantum Biopharma on 7 of the 9 factors compared between the two stocks.How does Aptorum Group compare to Lipocine?Lipocine (NASDAQ:LPCN) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations. Which has more risk & volatility, LPCN or APM? Lipocine has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Aptorum Group has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Which has higher valuation & earnings, LPCN or APM? Aptorum Group has lower revenue, but higher earnings than Lipocine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipocine$2.00M9.26-$9.63M-$1.88N/AAptorum Group$430K12.64-$1.36MN/AN/A Is LPCN or APM more profitable? Aptorum Group has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Aptorum Group's return on equity of 0.00% beat Lipocine's return on equity.Company Net Margins Return on Equity Return on Assets Lipocine-571.18% -66.70% -59.39% Aptorum Group N/A N/A N/A Do insiders and institutionals hold more shares of LPCN or APM? 9.1% of Lipocine shares are held by institutional investors. Comparatively, 3.8% of Aptorum Group shares are held by institutional investors. 6.4% of Lipocine shares are held by insiders. Comparatively, 64.0% of Aptorum Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor LPCN or APM? In the previous week, Lipocine had 4 more articles in the media than Aptorum Group. MarketBeat recorded 4 mentions for Lipocine and 0 mentions for Aptorum Group. Lipocine's average media sentiment score of 0.00 equaled Aptorum Group'saverage media sentiment score. Company Overall Sentiment Lipocine Neutral Aptorum Group Neutral Do analysts rate LPCN or APM? Lipocine currently has a consensus price target of $15.00, suggesting a potential upside of 566.67%. Given Lipocine's stronger consensus rating and higher probable upside, equities analysts plainly believe Lipocine is more favorable than Aptorum Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryLipocine beats Aptorum Group on 7 of the 13 factors compared between the two stocks. Get Aptorum Group News Delivered to You Automatically Sign up to receive the latest news and ratings for APM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APM vs. The Competition ExportMetricAptorum GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.44M$2.98B$6.29B$12.07BDividend YieldN/A1.98%2.80%5.32%P/E RatioN/A17.2420.6225.05Price / Sales12.64284.19545.5877.63Price / CashN/A56.3527.4837.30Price / Book0.393.909.736.60Net Income-$1.36M$74.99M$3.55B$335.50M7 Day Performance4.25%-4.71%-1.86%-1.91%1 Month Performance-3.33%-8.12%-3.69%-1.84%1 Year Performance-6.97%28.75%29.52%27.02% Aptorum Group Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APMAptorum Group0.4697 of 5 stars$0.86-0.1%N/A-10.0%$5.44M$430KN/A30Gap DownANEBAnebulo PharmaceuticalsN/A$0.52+13.0%$3.00+476.9%-50.5%$21.21MN/AN/A4XCURExicure0.6191 of 5 stars$3.31+2.0%N/A-69.6%$21.05M$500KN/A50Gap DownQNCXQuince Therapeutics2.2554 of 5 stars$1.22-3.6%$65.00+5,249.8%-88.3%$19.64MN/AN/A60News CoverageAnalyst UpgradeGap UpQNTMQuantum Biopharma0.2476 of 5 stars$5.09-2.1%N/A-38.8%$19.43MN/AN/AN/ANews CoverageGap Up Related Companies and Tools Related Companies ANEB Competitors XCUR Competitors QNCX Competitors QNTM Competitors LPCN Competitors KTTA Competitors LGVN Competitors COCP Competitors NCEL Competitors NAII Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APM) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptorum Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptorum Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
